There is vast potential for anti-neoplastic vaccines in cancer patients, and many studies are testing their effectiveness in a variety of cancers, from HER2 vaccines in breast and bladder cancer (NCT01730118) to MAGE-3 (NCT00290355), p53 (NCT00049218), and MUC1 (NCT02140996, NCT00415818, NCT03300817) vaccines in lung cancers and many more. This evidence concerns the gene MAGEA3 and cancer.